Top

Published in:

01-01-2014 | Clinical Study

Incidence and prognostic value of multiple gene promoter methylations in gliomas

Authors: Longzhou Zhang, Maode Wang, Wei Wang, Jun Mo

Published in: Journal of Neuro-Oncology | Issue 2/2014

Abstract

Aberrant CpG island methylation is a common phenomenon in malignancy. The methylation status of multiple tumor suppressor genes may serve as a biomarker for early diagnostics and the prediction of prognosis. In this study, we quantitatively determined the promoter methylation status of five tumor-related genes in tumor tissue and paired serum from 240 patients with gliomas. The relationship between hyper-methylation and clinic-pathological parameters was evaluated, and the prognostic value of the methylation status was determined. Hypermethylation in serum was shown to be accompanied by hypermethylation in paired tumor tissues. In both tumors and serum, methylation of polymerase-1 (PARP-1), SHP-1, DAPK-1 and TIMP-3 genes was at significantly higher levels in high-grade compared with low-grade gliomas, indicating that the promoter methylation status positively correlates with tumor grade. In malignant gliomas, the serum methylation levels of PARP-1, and SHP-1 together with IDH-1 mutations were found to be independent prognostic factors for overall survival. Moreover, hypermethylation of PARP-1 in serum correlated with a shorter progression-free survival time. These results suggest that hypermethylation in gliomas correlates with increased malignancy and poor prognosis. Analysis of the serum promoter methylation status of multiple genes could therefore be used as a biomarker for the detection and evaluation of the prognosis of glioma patients.

Tsou JA, Hagen JA, Carpenter CL et al (2002) DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21:5450–5461PubMedCrossRef

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692PubMedCrossRef

Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16(4):168–174PubMedCrossRef

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRef

Das PM, Singal R (2004) DNA methylation and cancer. J Clin Oncol 22:4632–4642PubMedCrossRef

Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4:707–717PubMedCrossRef

Lo KW, Kwong J, Hui AB et al (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61:3877–3881PubMed

Sato F, Meltzer SJ (2006) CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106:483–493PubMedCrossRef

Xing EP, Nie Y, Wang LD et al (1999) Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 20:77–84PubMedCrossRef

10.

Nie Y, Liao J, Zhao X et al (2002) Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 23:1713–1720PubMedCrossRef

11.

Ramirez JL, Taron M, Balana C et al (2003) Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst 48:34–41PubMed

12.

Chan KC, Lo YM (2007) Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer 96(5):681–685PubMedCentralPubMedCrossRef

13.

Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed

14.

Schwarzenbach H, Chun FK, Muller I et al (2008) Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int 102(2):253–258PubMedCrossRef

15.

Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102(45):16368–16373PubMedCrossRef

16.

Fujiwara K, Fujimoto N, Tabata M et al (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11(3):1219–1225PubMed

17.

Altman DG, Lausen B, Sauerbrei B et al (1994) Dangers of using ‘Optimal’ cutpoints in the valuation of prognostic factors. J Natl Cancer Inst 86:829–835PubMedCrossRef

18.

Miller R, Siegmund D (1982) Maximally selected Chi square statistics. Biometrics 38(4):1011–1016CrossRef

19.

Chan KC, Lo YM (2007) Circulating tumor-derived nucleic acids in cancer patients: potential applications as tumour makers. Br J Cancer 96:681–685PubMedCentralPubMedCrossRef

20.

Skvortsova TE, Rykova EY, Tamkovich SN et al (2006) Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumor-related gene methylation. Br J Cancer 94:1492–1495PubMedCentralPubMedCrossRef

21.

Lavon I, Refael M, Zelikovitch B et al (2010) Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-oncology 12:173–180PubMedCentralPubMedCrossRef

22.

Paci M, Bellesia E, Maramotti S et al (2009) Circulating plasma DNA as diagnostic biomarker in non-cell lung cancer. Lung Cancer 64:92–97PubMedCrossRef

23.

Amirian E, Liu Y, Michael E (2010) Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. Neuro Oncol 12:444–452PubMedCentralPubMed

24.

Okezie O, Kanu BH (2009) Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 3:39–52

25.

Ogino H, Nozaki T, Gunji A et al (2007) Loss of PARP-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics 8:41PubMedCentralPubMedCrossRef

26.

Pachkowski BF, Tano K, Afonin V et al (2009) Cells deficient in PARP-1 shows an accelerated accumulation of DNA single strand breaks, but not AP sites, over the PARP-1 proficient cells exposed to MMS. Mutat Res 671:93–99. doi:10.1016/j.mrfmmm.2009.09.006 PubMedCentralPubMedCrossRef

27.

Joseph A, Soto D, Deng C (2006) PARP-1 inhibitors: are they the long sought genetically specific drugs for BRCA1/2 associated breast cancers? Int J Med Sci 3:117–123

28.

Davis JD, Lin SY (2011) DNA damage and breast cancer. World J Clin Oncol 10:329–338CrossRef

29.

Wu C, Sun M, Liu L (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1–12PubMedCrossRef

30.

Oka T, Yoshino T, Hayashi K et al (2001) Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 159:1495–1505PubMedCrossRef

31.

Kim JH, Choi YD, Lee JS et al (2010) Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol 116:99–104PubMedCrossRef

32.

Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71:713–721PubMedCrossRef

33.

Hoffmann AC, Vallbohmer D, Prenzel K et al (2009) Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 135:1231–1237PubMedCrossRef

34.

Hu SL, Kong XY, Cheng ZD et al (2010) Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 96:726–733PubMed

35.

Wang Y, Zhang D, Zheng W et al (2008) Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112:1325–1336PubMedCrossRef

36.

Ebert MP, Mooney SH, Tonnes-Priddy L et al (2005) Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 7:771–778PubMedCentralPubMedCrossRef

37.

Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354PubMedCrossRef

38.

Kitange GJ, Carlson BL, Mladek AC et al (2009) Evaluation of MGMT Promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol 92:23–31PubMedCentralPubMedCrossRef

39.

Mineura K, Yanagisawa T, Wantanabe K et al (1996) Human brain tumor O⁶-methylguanine-DNA methytranseferase mRNA and its significance as indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer 69:420–425PubMedCrossRef

40.

Kim YH, Nobusawa S, Mittelbronn M et al (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708–2714PubMedCrossRef

41.

Sanoson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRef

42.

Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007PubMedCrossRef

43.

Juratli TA, Kirsch M, Roble K et al (2012) IDH1 mutations as an early and consistent marker in low-grade astrocytomas WHO grade and their consecutive secondary high-grade gliomas. J Neurooncol 108:403–410. doi:10.1007/s11060-012-0844-1 PubMedCrossRef

44.

Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCentralPubMedCrossRef

45.

Wojdacz TK (2007) Dobrovic A (2007) Methylation sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35:e41PubMedCentralPubMedCrossRef

46.

Liu W, Guan M, Bing S et al (2010) Rapid determination of AKAP12 promoter methylationn levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer. Clin Chim Acta 411:940–946PubMedCrossRef

47.

Smart A, Martin P (2006) The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Stud Hist Philos Biol Biomed Sci 37:589–601CrossRef

48.

Bremnes RM, Sirera R, Camps C (2005) Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49(1):1–12PubMedCrossRef

49.

Sunami E, Shinozaki M, Higano CS et al (2009) Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 55(3):559–567PubMedCrossRef

50.

Catarino R, Coelho A, Medeiros R (2012) Circulating DNA and NSCLC: old findings with new perspectives. J Thorac Dis 4(5): 442–443

Title: Incidence and prognostic value of multiple gene promoter methylations in gliomas
Authors: Longzhou Zhang
Maode Wang
Wei Wang
Jun Mo
Publication date: 01-01-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1301-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Incidence and prognostic value of multiple gene promoter methylations in gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma

Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI

Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Acknowledgement of reviewers 2012

Study of chromosome 9q gain, Notch pathway regulators and Tenascin-C in ependymomas